Merck & Co., Inc. Financial Highlights Package First Quarter 2021 Table of Contents Table 1: GAAP P&L..........................................................................1 Table 1a: GAAP P&L – Current Year and Prior Year by Quarter......2 Table 2a: GAAP to Non-GAAP Reconciliation 1Q21 ........................3 Table 2b: GAAP to Non-GAAP Reconciliation 1Q20.........................4 Table 3: Sales – Current Year and Prior Year by Quarter ...............5 Table 3a: Sales – U.S. / Ex- U.S. 1Q21.............................................6 Table 3b: Sales – Pharmaceutical Geographic Split .........................7 Table 4: Other (Income) Expense ....................................................8 -- 1 of 9 -- Sales 12,080 $ 12,057 $ 0% Costs, Expenses and Other Cost of sales 3,670 3,312 11% Selling, general and administrative 2,633 2,555 3% Research and development 2,465 2,209 12% Restructuring costs (1) 298 72 * Other (income) expense, net (448) 71 * Income Before Taxes 3,462 3,838 -10% Taxes on Income 276 619 Net Income 3,186 3,219 -1% Less: Net Income Attributable to Noncontrolling Interests 7 - Net Income Attributable to Merck & Co., Inc. 3,179 $ 3,219 $ -1% Earnings per Common Share Assuming Dilution 1.25 $ 1.26 $ -1% Average Shares Outstanding Assuming Dilution 2,541 2,547 Tax Rate (2) 8.0% 16.1% * 100% or greater MERCK & CO., INC. CONSOLIDATED STATEMENT OF INCOME - GAAP (AMOUNTS IN MILLIONS, EXCEPT PER SHARE FIGURES) (UNAUDITED) Table 1 (2) The effective income tax rate for the first quarter of 2021 reflects a net tax benefit of $237 million related to the settlement of certain federal income tax matters. (1) Represents separation and other related costs associated with restructuring activities under the company's formal restructuring programs. 1Q20 1Q21 GAAP % Change 1 -- 2 of 9 -- . . Sales 12,080 $ 12,057 $ 10,872 $ 12,551 $ 12,514 $ 47,994 $ 0% Costs, Expenses and Other Cost of sales 3,670 3,312 3,159 3,481 5,532 15,485 11% Selling, general and administrative 2,633 2,555 2,378 2,450 3,086 10,468 3% Research and development 2,465 2,209 2,123 3,390 5,838 13,558 12% Restructuring costs 298 72 83 114 309 578 * Other (income) expense, net (448) 71 (390) (312) (258) (886) * Income (Loss) Before Taxes 3,462 3,838 3,519 3,428 (1,993) 8,791 -10% Taxes on Income 276 619 509 483 99 1,709 Net Income (Loss) 3,186 3,219 3,010 2,945 (2,092) 7,082 -1% Less: Net Income Attributable to Noncontrolling Interests 7 - 8 4 2 15 Net Income (Loss) Attributable to Merck & Co., Inc. 3,179 $ 3,219 $ 3,002 $ 2,941 $ (2,094) $ 7,067 $ -1% Earnings (Loss) per Common Share Assuming Dilution (1) 1.25 $ 1.26 $ 1.18 $ 1.16 $ (0.83) $ 2.78 $ -1% Average Shares Outstanding Assuming Dilution (1) 2,541 2,547 2,536 2,538 2,530 2,541 Tax Rate 8.0% 16.1% 14.5% 14.1% -5.0% 19.4% * 100% or greater Sum of quarterly amounts may not equal year-to-date amounts due to rounding. (1) Because the company recorded a net loss in the fourth quarter of 2020, no potential dilutive common shares were used in the computation of loss per common share assuming dilution as the effect would have been anti-dilutive. 2Q 3Q 4Q Full Year 1Q 1Q 1Q 2021 2020 % Change MERCK & CO., INC. CONSOLIDATED STATEMENT OF INCOME - GAAP (AMOUNTS IN MILLIONS, EXCEPT PER SHARE FIGURES) (UNAUDITED) Table 1a 2 -- 3 of 9 -- Cost of sales 3,670 $ 517 27 188 (3) 732 2,938 $ Selling, general and administrative 2,633 218 3 221 2,412 Research and development 2,465 18 7 25 2,440 Restructuring costs 298 298 298 - Other (income) expense, net (448) (28) (561) (589) 141 Income Before Taxes 3,462 (725) (335) 561 (188) (687) 4,149 Income Tax Provision (Benefit) 276 (114) (4) (41) (4) 123 (4) (278) (4) (310) 586 Net Income 3,186 (611) (294) 438 90 (377) 3,563 Net Income Attributable to Merck & Co., Inc. 3,179 (611) (294) 438 90 (377) 3,556 Earnings per Common Share Assuming Dilution 1.25 $ (0.24) (0.12) 0.17 0.04 (0.15) 1.40 $ Tax Rate 8.0% 14.1% Only the line items that are affected by non-GAAP adjustments are shown. (1) Amount included in cost of sales primarily reflects expenses for the amortization of intangible assets. Amount included in selling, general and administrative expenses reflects approximately $208 million of expenses related to the company's planned spin-off of Organon & Co. and other acquisition and divestiture-related costs. Amount included in other (income) expense, net, primarily reflects royalty income, partially offset by an increase in the estimated fair value measurement of liabilities for contingent consideration related to the termination of the Sanofi-Pasteur MSD joint venture. (2) Amounts primarily include employee separation costs and accelerated depreciation associated with facilities to be closed or divested related to activities under the company's formal restructuring programs. (4) Represents the estimated tax impact on the reconciling items based on applying the statutory rate of the originating territory of the non-GAAP adjustments. Certain other items also include a $237 million net tax benefit related to the settlement of certain federal income tax matters. Non-GAAP Merck is providing certain non-GAAP information that excludes certain items because of the nature of these items and the impact they have on the analysis of underlying business performance and trends. Management believes that providing this information enhances investors’ understanding of the company’s results as it permits investors to understand how management assesses performance. Management uses these measures internally for planning and forecasting purposes and to measure the performance of the company along with other metrics. In addition, senior management’s annual compensation is derived in part using non-GAAP pretax income. This information should be considered in addition to, but not as a substitute for or superior to, information prepared in accordance with GAAP. Certain Other Items (3) Represents a charge for the discontinuation of COVID-19 development programs. MERCK & CO., INC. GAAP TO NON-GAAP RECONCILIATION FIRST QUARTER 2021 (AMOUNTS IN MILLIONS, EXCEPT PER SHARE FIGURES) (UNAUDITED) Table 2a GAAP Acquisition and Divestiture-Related Costs (1) Restructuring Costs (2) (Income) Loss from Investments in Equity Securities Adjustment Subtotal 3 -- 4 of 9 -- Cost of sales 3,312 $ 407 68 475 2,837 $ Selling, general and administrative 2,555 278 11 289 2,266 Research and development 2,209 40 17 57 2,152 Restructuring costs 72 72 72 - Other (income) expense, net 71 (11) (87) (98) 169 Income Before Taxes 3,838 (714) (168) 87 (795) 4,633 Income Tax Provision (Benefit) 619 (175) (3) (7) (3) 19 (3) (163) 782 Net Income 3,219 (539) (161) 68 (632) 3,851 Net Income Attributable to Merck & Co., Inc. 3,219 (539) (161) 68 (632) 3,851 Earnings per Common Share Assuming Dilution 1.26 $ (0.21) (0.06) 0.02 (0.25) 1.51 $ Tax Rate 16.1% 17.0% Only the line items that are affected by non-GAAP adjustments are shown. Table 2b MERCK & CO., INC. GAAP TO NON-GAAP RECONCILIATION* FIRST QUARTER 2020 (AMOUNTS IN MILLIONS, EXCEPT PER SHARE FIGURES) (UNAUDITED) Merck is providing certain non-GAAP information that excludes certain items because of the nature of these items and the impact they have on the analysis of underlying business performance and trends. Management believes that providing this information enhances investors’ understanding of the company’s results as it permits investors to understand how management assesses performance. Management uses these measures internally for planning and forecasting purposes and to measure the performance of the company along with other metrics. In addition, senior management’s annual compensation is derived in part using non-GAAP pretax income. This information should be considered in addition to, but not as a substitute for or superior to, information prepared in accordance with GAAP. (1) Amount included in cost of sales primarily reflects expenses for the amortization of intangible assets. Amount included in selling, general and administrative expenses reflects approximately $165 million of expenses related to the company's planned spin-off of Organon & Co., approximately $95 million of costs related to the acquisition of ArQule, Inc., and other acquisition and divestiture-related costs. Amount included in research and development expenses primarily reflects expenses related to a net increase in the estimated fair value measurement of liabilities for contingent consideration. Amount included in other (income) expense, net, primarily reflects royalty income, partially offset by an increase in the estimated fair value measurement of liabilities for contingent consideration related to the termination of the Sanofi-Pasteur MSD joint venture. (2) Amounts primarily include employee separation costs and accelerated depreciation associated with facilities to be closed or divested related to activities under the company's formal restructuring programs. (3) Represents the estimated tax impact on the reconciling items based on applying the statutory rate of the originating territory of the non-GAAP adjustments. GAAP Acquisition and Divestiture-Related Costs (1) Restructuring Costs (2) (Income) Loss from Investments in Equity Securities Adjustment Subtotal Non-GAAP *As previously disclosed, beginning in 2021, the Company has changed the treatment of certain items for purposes of its non-GAAP reporting. Historically, Merck’s non-GAAP results excluded the amortization of intangible assets recognized in connection with business acquisitions, but did not exclude the amortization of intangibles originating from collaborations, asset acquisitions or licensing arrangements. In 2021, Merck’s non-GAAP results no longer differentiate between the nature of intangibles amortization and exclude all amortization of intangible assets. Also, beginning in 2021, Merck’s non-GAAP results exclude realized and unrealized gains and losses from investments in equity securities either owned directly or through ownership interests in investment funds. These amounts are difficult to predict and can fluctuate significantly period to period affecting comparability of results. Non-GAAP results for the comparable periods of 2020 have been recast to conform to the new presentation. 4 -- 5 of 9 -- 2021 1Q 1Q 2Q 3Q 4Q Full Year Nom % Ex-Exch % TOTAL SALES (1) $12,080 $12,057 $10,872 $12,551 $12,514 $47,994 - -1 PHARMACEUTICAL 10,675 10,655 9,679 11,320 11,367 43,021 - -3 Oncology Keytruda 3,899 3,284 3,388 3,715 3,993 14,380 19 16 Alliance Revenue – Lynparza (2) 228 145 178 196 206 725 57 51 Alliance Revenue – Lenvima (2) 130 128 151 142 158 580 1 -1 Vaccines (3) Gardasil / Gardasil 9 917 1,097 656 1,187 998 3,938 -16 -20 ProQuad / M-M-R II / Varivax 449 435 378 576 488 1,878 3 2 Pneumovax 23 171 256 117 375 339 1,087 -33 -36 RotaTeq 158 222 168 210 196 797 -29 -29 Vaqta 34 60 28 51 31 170 -43 -44 Hospital Acute Care Bridion 340 299 224 320 355 1,198 14 11 Prevymis 82 60 63 77 80 281 37 31 Noxafil 67 94 73 79 82 329 -29 -32 Primaxin 65 51 64 74 62 251 26 17 Cancidas 57 55 43 50 65 213 4 1 Invanz 57 64 43 51 53 211 -12 -11 Zerbaxa (8) 37 32 43 19 130 -121 -120 Immunology Simponi 214 215 191 209 223 838 - -8 Remicade 85 88 73 82 88 330 -3 -9 Neuroscience Belsomra 79 79 84 81 83 327 - -4 Virology Isentress / Isentress HD 209 245 196 205 211 857 -15 -15 Cardiovascular Zetia 92 145 137 103 98 482 -37 -41 Vytorin 41 53 39 47 43 182 -23 -27 Atozet 112 122 115 111 105 453 -9 -16 Alliance Revenue - Adempas (4) 74 53 79 83 65 281 38 38 Adempas (5) 55 56 57 55 53 220 -2 -10 Diabetes (6) Januvia 809 774 854 821 857 3,306 5 2 Janumet 486 503 490 506 472 1,971 -3 -6 Women's Health Implanon / Nexplanon 183 195 132 189 165 680 -6 -7 NuvaRing 45 63 63 58 53 236 -28 -30 Diversified Brands Singulair 107 155 100 82 124 462 -31 -35 Cozaar / Hyzaar 90 102 98 91 94 386 -12 -16 Arcoxia 56 70 65 68 54 258 -20 -22 Follistim AQ 52 41 44 50 57 193 25 21 Nasonex 43 71 49 41 57 218 -39 -40 Other Pharmaceutical (7) 1,197 1,338 1,207 1,292 1,340 5,173 -11 -13 ANIMAL HEALTH 1,418 1,214 1,101 1,220 1,168 4,703 17 15 Livestock 819 739 648 758 794 2,939 11 9 Companion Animals 599 475 453 462 374 1,764 26 24 Other Revenues (8) (13) 188 92 11 (21) 270 -107 -21 (6) Total Diabetes sales were $1,363 million in the first quarter of 2021 and $1,353 million, $1,418 million, $1,405 million and $1,412 million in the first, second, third and fourth quarters of 2020, respectively. (7) Includes Pharmaceutical products not individually shown above. (8) Other Revenues are comprised primarily of third-party manufacturing sales and miscellaneous corporate revenues, including revenue hedging activities. Sum of quarterly amounts may not equal year-to-date amounts due to rounding. (1) Only select products are shown. (2) Alliance Revenue represents Merck’s share of profits, which are product sales net of cost of sales and commercialization costs. (3) Total Vaccines sales were $1,809 million in the first quarter of 2021 and $2,155 million, $1,418 million, $2,521 million and $2,163 million in the first, second, third and fourth quarters of 2020, respectively. (4) Alliance Revenue represents Merck's share of profits from sales in Bayer's marketing territories, which are product sales net of cost of sales and commercialization costs. (5) Net product sales in Merck's marketing territories. 2020 1Q MERCK & CO., INC. FRANCHISE / KEY PRODUCT SALES (AMOUNTS IN MILLIONS) (UNAUDITED) Table 3 5 -- 6 of 9 -- 1Q 2021 1Q 2020 % Change 1Q 2021 1Q 2020 % Change 1Q 2021 1Q 2020 % Change TOTAL SALES (1) $12,080 $12,057 - $5,136 $5,137 - $6,943 $6,920 - PHARMACEUTICAL 10,675 10,655 - 4,641 4,714 -2 6,034 5,941 2 Oncology Keytruda 3,899 3,284 19 2,181 1,906 14 1,718 1,378 25 Alliance Revenue - Lynparza (2) 228 145 57 118 85 39 110 60 81 Alliance Revenue - Lenvima (2) 130 128 1 85 90 -5 44 38 17 Vaccines (3) Gardasil / Gardasil 9 917 1,097 -16 313 461 -32 604 636 -5 ProQuad / M-M-R II / Varivax 449 435 3 333 333 - 117 102 14 Pneumovax 23 171 256 -33 73 182 -60 99 75 32 RotaTeq 158 222 -29 118 140 -16 41 82 -50 Vaqta 34 60 -43 25 30 -17 9 30 -70 Hospital Acute Care Bridion 340 299 14 167 143 17 173 157 10 Prevymis 82 60 37 35 26 33 47 33 41 Noxafil 67 94 -29 15 8 96 52 87 -40 Primaxin 65 51 26 -97 65 51 27 Cancidas 57 55 4 3 3 -4 55 52 5 Invanz 57 64 -12 4 6 -26 52 59 -11 Zerbaxa (8) 37 -121 (2) 20 -110 (6) 16 -135 Immunology Simponi 214 215 - 214 215 - Remicade 85 88 -3 85 88 -3 Neuroscience Belsomra 79 79 - 18 27 -33 61 53 17 Virology Isentress / Isentress HD 209 245 -15 71 75 -6 138 170 -19 Cardiovascular Zetia 92 145 -37 2 (2) -199 90 147 -39 Vytorin 41 53 -23 2 3 -29 38 50 -23 Atozet 112 122 -9 112 122 -9 Alliance Revenue - Adempas (4) 74 53 38 68 49 40 6 5 22 Adempas (5) 55 56 -2 55 56 -2 Diabetes (6) Januvia 809 774 5 348 355 -2 461 419 10 Janumet 486 503 -3 84 113 -26 401 390 3 Women's Health Implanon / Nexplanon 183 195 -6 141 149 -6 42 45 -6 NuvaRing 45 63 -28 21 26 -20 24 37 -34 Diversified Brands Singulair 107 155 -31 4 5 -8 102 151 -32 Cozaar / Hyzaar 90 102 -12 3 7 -56 87 95 -8 Arcoxia 56 70 -20 56 70 -20 Follistim AQ 52 41 25 25 21 23 27 21 28 Nasonex 43 71 -39 2 6 -65 41 65 -37 Other Pharmaceutical (7) 1,197 1,338 -11 384 447 -14 814 886 -8 ANIMAL HEALTH 1,418 1,214 17 437 384 14 981 830 18 Livestock 819 739 11 157 162 -3 662 577 15 Companion Animals 599 475 26 280 222 26 319 253 26 Other Revenues (8) (13) 188 -107 58 39 51 (72) 149 -149 Sum of U.S. plus international may not equal global due to rounding. (4) Alliance Revenue represents Merck's share of profits from sales in Bayer's marketing territories, which are product sales net of cost of sales and commercialization costs. (5) Net product sales in Merck's marketing territories. (6) Total Diabetes sales were $1,363 million and $1,353 million on a global basis in the first quarter of 2021 and 2020, respectively. (7) Includes Pharmaceutical products not individually shown above. (8) Other Revenues are comprised primarily of third-party manufacturing sales and miscellaneous corporate revenues, including revenue hedging activities. (3) Total Vaccines sales were $1,809 million and $2,155 million on a global basis in the first quarter of 2021 and 2020, respectively. MERCK & CO., INC. FRANCHISE / KEY PRODUCT SALES FIRST QUARTER 2021 (AMOUNTS IN MILLIONS) (UNAUDITED) Table 3a Global U.S. International (1) Only select products are shown. (2) Alliance Revenue represents Merck’s share of profits, which are product sales net of cost of sales and commercialization costs. 6 -- 7 of 9 -- 2021 % Change TOTAL PHARMACEUTICAL $10,675 $10,655 $9,679 $11,320 $11,367 $43,021 - United States 4,641 4,714 4,270 5,218 5,247 19,449 -2 % Pharmaceutical Sales 43.5% 44.2% 44.1% 46.1% 46.2% 45.2% Europe (1) 2,663 2,543 2,196 2,549 2,709 9,997 5 % Pharmaceutical Sales 24.9% 23.9% 22.7% 22.5% 23.8% 23.2% China 894 846 811 990 888 3,534 6 % Pharmaceutical Sales 8.4% 7.9% 8.4% 8.7% 7.8% 8.2% Japan 708 789 847 805 847 3,288 -10 % Pharmaceutical Sales 6.6% 7.4% 8.8% 7.1% 7.5% 7.6% Asia Pacific (other than China and Japan) 614 613 555 601 603 2,372 - % Pharmaceutical Sales 5.8% 5.8% 5.7% 5.3% 5.3% 5.5% Eastern Europe/Middle East/Africa 463 490 416 419 365 1,689 -5 % Pharmaceutical Sales 4.3% 4.6% 4.3% 3.7% 3.2% 3.9% Latin America 422 419 399 477 474 1,768 1 % Pharmaceutical Sales 4.0% 3.9% 4.1% 4.2% 4.2% 4.1% Canada 203 212 160 216 194 782 -4 % Pharmaceutical Sales 1.9% 2.0% 1.7% 1.9% 1.7% 1.8% Other 67 29 25 45 40 142 131 % Pharmaceutical Sales 0.6% 0.3% 0.3% 0.4% 0.4% 0.3% 1Q Sum of quarterly amounts may not equal year-to-date amounts due to rounding. (1) Europe primarily represents all European Union countries, the European Union accession markets and the United Kingdom. 1Q 1Q 2Q 3Q 4Q Full Year 2020 MERCK & CO., INC. PHARMACEUTICAL GEOGRAPHIC SALES (AMOUNTS IN MILLIONS) (UNAUDITED) Table 3b 7 -- 8 of 9 -- OTHER (INCOME) EXPENSE, NET 1Q21 1Q20 Interest income (11) $ (25) $ Interest expense 200 212 Exchange losses 47 54 Income from investments in equity securities, net (1) (574) (52) Net periodic defined benefit plan (credit) cost other than service cost (89) (90) Other, net (21) (28) Total (448) $ 71 $ (1) Includes realized and unrealized gains and losses from investments in equity securities either owned directly or through ownership interests in investment funds. Unrealized gains and losses from investments that are directly owned are determined at the end of the reporting period, while ownership interests in investment funds are accounted for on a one quarter lag. MERCK & CO., INC. OTHER (INCOME) EXPENSE, NET - GAAP (AMOUNTS IN MILLIONS) (UNAUDITED) Table 4 8 -- 9 of 9 --